Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) Shares Sold by Nuveen Asset Management LLC

Nuveen Asset Management LLC cut its stake in shares of Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS - Free Report) by 10.8% during the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 125,539 shares of the company's stock after selling 15,186 shares during the quarter. Nuveen Asset Management LLC owned about 0.33% of Tarsus Pharmaceuticals worth $6,951,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also made changes to their positions in TARS. Crowley Wealth Management Inc. acquired a new position in shares of Tarsus Pharmaceuticals during the 4th quarter worth $25,000. R Squared Ltd acquired a new position in shares of Tarsus Pharmaceuticals during the 4th quarter worth $53,000. Quarry LP acquired a new position in shares of Tarsus Pharmaceuticals during the 4th quarter worth $166,000. HighTower Advisors LLC acquired a new position in shares of Tarsus Pharmaceuticals during the 4th quarter worth $207,000. Finally, Summit Investment Advisors Inc. grew its stake in Tarsus Pharmaceuticals by 6.8% in the 4th quarter. Summit Investment Advisors Inc. now owns 3,848 shares of the company's stock valued at $213,000 after acquiring an additional 244 shares during the last quarter. 90.01% of the stock is owned by institutional investors and hedge funds.

Analysts Set New Price Targets

A number of equities research analysts recently commented on the stock. HC Wainwright raised shares of Tarsus Pharmaceuticals to a "buy" rating and set a $72.00 price objective on the stock in a research note on Tuesday. Guggenheim increased their price objective on shares of Tarsus Pharmaceuticals from $78.00 to $84.00 and gave the company a "buy" rating in a research note on Friday, May 2nd. Jefferies Financial Group increased their price objective on shares of Tarsus Pharmaceuticals from $54.00 to $58.00 and gave the company a "buy" rating in a research note on Thursday, March 6th. Wall Street Zen lowered shares of Tarsus Pharmaceuticals from a "buy" rating to a "hold" rating in a report on Thursday, May 22nd. Finally, Barclays reduced their target price on shares of Tarsus Pharmaceuticals from $62.00 to $60.00 and set an "overweight" rating on the stock in a report on Wednesday, February 26th. Two equities research analysts have rated the stock with a hold rating, five have given a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat.com, the company has an average rating of "Moderate Buy" and an average price target of $66.17.

Tarsus Pharmaceuticals Trading Down 1.2%

NASDAQ TARS traded down $0.50 during mid-day trading on Friday, hitting $42.94. The company's stock had a trading volume of 428,338 shares, compared to its average volume of 702,325. Tarsus Pharmaceuticals, Inc. has a 52-week low of $20.08 and a 52-week high of $57.28. The stock's fifty day simple moving average is $46.93 and its two-hundred day simple moving average is $48.92. The company has a debt-to-equity ratio of 0.30, a current ratio of 5.42 and a quick ratio of 5.38. The firm has a market capitalization of $1.80 billion, a P/E ratio of -11.27 and a beta of 0.94.

Tarsus Pharmaceuticals (NASDAQ:TARS - Get Free Report) last posted its quarterly earnings results on Thursday, May 1st. The company reported ($0.64) EPS for the quarter, beating the consensus estimate of ($0.69) by $0.05. Tarsus Pharmaceuticals had a negative net margin of 103.64% and a negative return on equity of 55.86%. The firm had revenue of $78.34 million for the quarter, compared to analyst estimates of $72.50 million. Research analysts expect that Tarsus Pharmaceuticals, Inc. will post -3.17 EPS for the current year.

Insider Activity at Tarsus Pharmaceuticals

In other news, CEO Bobak R. Azamian sold 6,000 shares of Tarsus Pharmaceuticals stock in a transaction that occurred on Monday, March 24th. The shares were sold at an average price of $50.00, for a total transaction of $300,000.00. Following the sale, the chief executive officer now owns 824,106 shares in the company, valued at $41,205,300. This trade represents a 0.72% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, General Counsel Bryan Wahl sold 3,341 shares of Tarsus Pharmaceuticals stock in a transaction on Tuesday, March 18th. The stock was sold at an average price of $46.29, for a total transaction of $154,654.89. Following the completion of the sale, the general counsel now owns 58,057 shares of the company's stock, valued at approximately $2,687,458.53. This trade represents a 5.44% decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 32,542 shares of company stock worth $1,581,173. Company insiders own 8.25% of the company's stock.

About Tarsus Pharmaceuticals

Tarsus Pharmaceuticals, Inc, a commercial stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutic candidates for eye care in the United States. The company's lead product candidate is XDEMVY, a novel therapeutic for the treatment of blepharitis caused by the infestation of Demodex mites, as well as to treat meibomian gland disease.